387 related articles for article (PubMed ID: 32390114)
1. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry.
Schrezenmeier H; Röth A; Araten DJ; Kanakura Y; Larratt L; Shammo JM; Wilson A; Shayan G; Maciejewski JP
Ann Hematol; 2020 Jul; 99(7):1505-1514. PubMed ID: 32390114
[TBL] [Abstract][Full Text] [Related]
2. Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry.
Dingli D; Maciejewski JP; Larratt L; Go RS; Höchsmann B; Zu K; Gustovic P; Kulagin AD
Ann Hematol; 2023 Jul; 102(7):1637-1644. PubMed ID: 37199789
[TBL] [Abstract][Full Text] [Related]
3. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
[TBL] [Abstract][Full Text] [Related]
4. Analysis of baseline characteristics, disease burden and long-term follow-up of 167 patients with Paroxysmal Nocturnal Hemoglobinuria at a single center in Brazil.
de Azambuja AP; Oliveira MM; Bitencourt MA; Bonfim C; Malvezzi M; Pasquini R
Blood Cells Mol Dis; 2021 Dec; 92():102605. PubMed ID: 34537447
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Schrezenmeier H; Muus P; Socié G; Szer J; Urbano-Ispizua A; Maciejewski JP; Brodsky RA; Bessler M; Kanakura Y; Rosse W; Khursigara G; Bedrosian C; Hillmen P
Haematologica; 2014 May; 99(5):922-9. PubMed ID: 24488565
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness of eculizumab: Data from the International PNH Registry.
Terriou L; Lee JW; Forsyth C; Griffin M; Szer J; Röth A; Gustovic P; Metzger J; Patel AS; Patriquin CJ
Eur J Haematol; 2023 Nov; 111(5):796-804. PubMed ID: 37712908
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
[TBL] [Abstract][Full Text] [Related]
8. Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation.
Wang HC; Kuo CY; Liu IT; Chen TY; Chang YH; Lin SJ; Cho SF; Liu YC; Liu TC; Lin SF; Chang CS
Kaohsiung J Med Sci; 2017 Aug; 33(8):405-410. PubMed ID: 28811010
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
[TBL] [Abstract][Full Text] [Related]
10. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.
Cella D; Johansson P; Ueda Y; Tomazos I; Gustovic P; Wang A; Patel AS; Schrezenmeier H
J Patient Rep Outcomes; 2023 Jul; 7(1):63. PubMed ID: 37405515
[TBL] [Abstract][Full Text] [Related]
11. Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria.
Shingai N; Mizumaki H; Najima Y; Yamada Y; Tran DC; Haraguchi K; Toya T; Okuyama Y; Doki N; Nannya Y; Ogawa S; Nakao S
Front Immunol; 2023; 14():1329403. PubMed ID: 38288112
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure.
Hosokawa K; Ishiyama K; Ikemoto T; Sugimori C; Noji H; Shichishima T; Obara N; Chiba S; Ninomiya H; Nguyen MAT; Shirasugi Y; Nakamura Y; Ando K; Ueda Y; Yonemura Y; Kawaguchi T; Nishimura JI; Kanakura Y; Nakao S
Ann Hematol; 2021 Aug; 100(8):1975-1982. PubMed ID: 33095337
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study.
Du Y; Yang Y; Yang C; Chen M; Han B
Hematology; 2022 Dec; 27(1):113-121. PubMed ID: 35068377
[TBL] [Abstract][Full Text] [Related]
14. Evolution patterns of paroxysmal nocturnal hemoglobinuria clone and clinical implications in acquired bone marrow failure.
Lian Y; Shi J; Nie N; Huang Z; Shao Y; Zhang J; Huang J; Li X; Ge M; Jin P; Wang M; Zheng Y
Exp Hematol; 2019 Sep; 77():41-50. PubMed ID: 31472171
[TBL] [Abstract][Full Text] [Related]
15. The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria.
Ware RE; Nishimura J; Moody MA; Smith C; Rosse WF; Howard TA
Blood; 1998 Oct; 92(7):2541-50. PubMed ID: 9746796
[TBL] [Abstract][Full Text] [Related]
16. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure.
Raza A; Ravandi F; Rastogi A; Bubis J; Lim SH; Weitz I; Castro-Malaspina H; Galili N; Jawde RA; Illingworth A
Cytometry B Clin Cytom; 2014 May; 86(3):175-82. PubMed ID: 24227693
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience.
Goren Sahin D; Akay OM; Keklik M; Okan V; Karakus A; Demir C; Erkurt MA; Ilkkilic K; Yildirim R; Akgun Cagliyan G; Aksu S; Dogu MH; Dal MS; Karakus V; Gemici AI; Terzi H; Kelkitli E; Sivgin S; Unal A; Yilmaz M; Ayyildiz O; Korkmaz S; Eser B; Altuntas F
Ann Hematol; 2021 Jul; 100(7):1667-1675. PubMed ID: 33988739
[TBL] [Abstract][Full Text] [Related]
18. CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria.
Sutherland DR; Richards SJ; Ortiz F; Nayyar R; Benko M; Marinov I; Illingworth A
Cytometry B Clin Cytom; 2020 Mar; 98(2):179-192. PubMed ID: 31705743
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
Kim JS; Jang JH; Jo DY; Ahn SY; Yoon SS; Lee JH; Kim SH; Choi CW; Shin HJ; Kim MK; Lee JH; Mun YC; Kong JH; Hyun B; Nam H; Kim E; Kwak MJ; Won YK; Lee JW
J Korean Med Sci; 2023 Oct; 38(41):e328. PubMed ID: 37873628
[TBL] [Abstract][Full Text] [Related]
20. Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab.
Kang KW; Moon H; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Kim BS; Lee J; Park Y
Ann Hematol; 2020 Jul; 99(7):1493-1503. PubMed ID: 32542443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
